C

Caidya

Global CRO delivering end-to-end clinical development

Study Manager

Full-TimeUpdated on 10/21/2026
No salary listed
Senior
Bachelor's
Beijing, China
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A minimum of a Bachelor of Science or Bachelor of Arts in a biomedical discipline, or equivalent education/training, is required.
  • At least 5 years of experience in clinical practices.
  • Good working knowledge of Good Clinical Practices, monitoring, the clinical drug development process, and the country regulatory environment.
  • Experience with clinical research methodology, including study design, study monitoring, and data analysis.
  • Extensive knowledge of the clinical development process, including in-depth knowledge and understanding of Good Clinical Practice principles.
  • Knowledge of clinical development processes and study design concepts and principles, and their application to managing and running studies.
  • Knowledge of global and local regulatory requirements, disease areas, and technical areas relevant to clinical studies.
  • Ability to manage studies and processes to agreed quality standards and timelines.
  • Ability to proactively identify and mitigate risks at the study and site levels.
  • Effective verbal and written communication with colleagues and associates inside and outside the organization.
Responsibilities
  • Conduct country- and study-level feasibility assessments and review Pre-Trial Assessment output to ensure appropriate site selection in China.
  • Provide operational input to protocol design to ensure operational feasibility.
  • Develop realistic, detailed study startup and monitoring plans.
  • Develop study-level recruitment and retention strategies and plans, and oversee implementation, including site-level plans, tools, and advertising materials.
  • Assess and oversee site activation plans to ensure timely site readiness, including Clinical Site Agreements, Ethics Committee approvals, and regulatory documentation.
  • Assess subject enrollment and discontinuations on an ongoing basis to inform accurate financial planning forecasts.
  • Generate study- and country-level informed consent documents and review site-level informed consent documents as appropriate.
  • Deliver studies against approved plans.
  • Coordinate study and protocol training and investigator meetings.
  • Serve as the technical expert for study management systems and processes.
  • Champion harmonized, consistent processes and excellence in study management deliverables to achieve cost-effective, timely, high-quality clinical trial data aligned with global goals.
  • Prepare HGRAC submission packages in collaboration with the HGRAC taskforce team.
  • Help address significant quality events and other patient- or site-level quality issues.
  • Monitor site performance using appropriate tools and resources, including study metrics, site health, and risk-based monitoring, and take appropriate mitigating actions.
  • Lead site- and country-level risk assessments for studies, including identification of mitigations and controls.
  • Conduct and report oversight activities, including remote and onsite visits, in accordance with Pfizer requirements and standards.
  • Perform additional oversight visits or reviews based on issues arising during a study and on analytics and visualization outputs.
  • Develop and provide key inputs to Clinical Trial Budgets, including per-subject costs.
  • Manage study budget phasing and tracking.
  • Develop study- and country-level Clinical Site Agreement templates and review and approve site agreements and contracts.
  • Review and approve payments to investigators and vendors.
  • Collaborate with the Supply Chain Lead to develop and complete requests for clinical supplies.
  • Work with the Supply Chain Lead to ensure clinical trial drug supplies are ordered, produced, labeled, and supplied on time.
  • Approve and oversee drug supply management, manage the flow of drug supply to sites, and set up the Integrated Voice Response System with the Supply Chain Lead.
  • Serve as a resource to the study team for study-specific audits and inspections.
  • Lead inspection-readiness activities related to study management and site readiness.
  • Support study-level submission readiness as needed.
Desired Qualifications
  • Prior study management and/or study coordination experience.
  • Advanced education and/or training/experience.

About the company

Caidya is a global contract research organization that provides outsourced clinical development services for biopharmaceutical and medical device companies. It covers the full lifecycle from pre-IND strategy and early-phase development through late-stage trials, regulatory submissions, and post-marketing surveillance, delivered via flexible models like standalone projects, full-service partnerships, and functional service provider arrangements, supported by its Clarity data platform that offers near real-time trial visibility and compatibility with Medidata Rave and Veeva. Its competitive edge comes from the merged legacy of Clinipace and dMed Global, strong leadership under Dr. Lingshi Tan, a broad global footprint including North America and China, and an emphasis on data-driven, transparent trial delivery. The goal is to help clients bring therapies to market efficiently and compliantly through high-quality, scalable trial execution across global programs.

Company Size

201-500

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$322.2M

Headquarters

Morrisville, North Carolina

Founded

2003

Get referred to Caidya

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 NMPA accepted partner MediLink's Tam-Peli NDA, validating China execution.
  • Caidya’s APAC-heavy model fits sponsors needing China speed and regulatory navigation.
  • Rubicon’s $165 million 2025 growth capital still funds expansion and integration.

What critics are saying

  • Combining Caidya and Simbec-Orion creates integration failure risk through 2026-2027.
  • CRO rivals Fortrea, ICON, and Medpace outspend Caidya on scale and technology.
  • Failed integration traps Caidya as a subscale CRO and forces retrenchment.

What makes Caidya unique

  • June 30, 2026 deal with Simbec-Orion adds Phase I clinical pharmacology to Caidya.
  • Barbara Lopez Kunz now runs a CRO spanning Europe, Americas, APAC, and China.
  • Michael Clay’s February 2026 COO hire deepens global delivery across 60 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Business Wire
Jul 1st, 2026
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution....

Associated Press
Feb 17th, 2026
Caidya appoints Michael Clay as COO to strengthen global clinical trial operations across Asia-Pacific

Caidya, a global clinical research organisation, has appointed Michael Clay as chief operating officer. Clay will oversee global operational delivery, client engagement and execution strategy across the US, Europe and Asia-Pacific. Clay brings extensive experience leading global clinical programmes across more than 60 countries, with particular expertise in Asia-Pacific operations. Most recently, he served as senior vice president of Global Project Delivery at Fortrea, where he managed over 500 global clinical trials. The appointment strengthens Caidya's operational capabilities, particularly in China and the broader APAC region. Caidya operates in more than 20 countries and conducts studies across over 50 countries, focusing on complex therapeutic areas including oncology, haematology and rare diseases.

Business Wire
Jan 16th, 2025
Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders.

Business Wire
Jan 13th, 2025
Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya announces $165 million strategic growth investment from Rubicon Founders.

FinSMEs
Jul 10th, 2021
dMed-Clinipace Closes US$50M Series C+ Financing

dMed-Clinipace, a Shangai, China- and Morrisville, NC-based global full-service Clinical Contract Research Organization (CRO), closed a US$50m Series C+ financing. The round was led by Springhill Fund, with participation from funds managed by Rock Springs Capital and Superstring Capital. They joined Series C lead investor Fidelity Management and Research Company LLC as well as other new […]